Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). - Concepedia

Concepedia

Publication | Closed Access

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

49

Citations

0

References

2011

Year

Robert M. Jotte, Joachim von Pawel, David R. Spigel, Mark A. Socinski, M. O’Brien, Eugene Paschold, J. Mezger, Martin Steins, Lionel Bosquée, Jeffrey A. Bubis,

Journal of Clinical Oncology

Abstract

7000